

North America Fill Finish Manufacturing Market Forecast to 2030 - Regional Analysis - by Product (Consumables {Prefilled Syringes, Glass Vial/Plastic Vials, Cartridges, and Others} and Instruments), Modality (Recombinant Proteins, Monoclonal Antibodies, Vaccines, Cell Therapies and Biological Therapies, Gene Therapies, and Others), and End User (Contract Manufacturing Organizations, Biopharmaceutical Companies, and Others)

<https://marketpublishers.com/r/NAC913650658EN.html>

Date: June 2024

Pages: 98

Price: US\$ 2,485.00 (Single User License)

ID: NAC913650658EN

Abstracts

The North America fill finish manufacturing market was valued at US\$ 3,439.58 million in 2022 and is expected to reach US\$ 6,505.56 million by 2030; it is estimated to grow at a CAGR of 8.3% from 2022 to 2030 .

Growing Adoption of Prefilled Syringes for Parenteral Administration Fuels North America Fill Finish Manufacturing Market

Parenteral administration is one of the most prominent routes chosen to stimulate immediate immune response and ensure the complete bioavailability of pharmaceutical products. A steady rise in the development and market availability of parenteral drugs has propelled the demand for advanced, cost-effective drug delivery devices that promise ease of administration. The benefits of prefilled syringes over traditional delivery systems include easy administration, improved safety, accurate dosing, and reduced contamination risks. Among drug delivery devices, prefilled syringes represent one of the fastest-growing primary packaging formats, which are designed for dose administration. In the past ten years, there has been an evident increase in the

development of parenteral drugs (especially with the introduction of several classes of biologics), which has resulted in approximately three-fold increase in the consumption of prefilled syringes. The sustained preference for the prefilled syringes is attributed to the safety and ease of use of these products. Recent variants are designed with provisions to reduce errors in dosing, risk of occlusions, leakage of fluids (i.e., extravasation), and inflammation of veins (phlebitis). Owing to the benefits mentioned above, several injectable drugs—Humira, Enbrel, Avastin, PREVNAR 13, ALPROLIX, and Benefix, among others—diluent and other products requiring parenteral administration are packaged in prefilled syringes.

Over the past seven years, ~90 drugs have been approved in the prefilled syringe packaging form across different geographies, including North America, Europe, and Asia Pacific. Several drugs in the clinical stages of drug development are being evaluated in combination with prefilled syringes.

The loading of sterile drugs into prefilled syringes is considered one of the most crucial steps in the pharmaceutical production process. Proper fill-finish operations are necessarily carried out under aseptic conditions to maintain pharmacological efficacy and quality and to ensure the safety of end users. The prefilled syringe filling is a complex operation as it requires extremely close monitoring of both the syringe fill volume and the headspace between the liquid filled in the syringe and the bottom of the plunger. In addition, the rise in complexity of small molecule APIs and the increasing diversity of biological drugs contribute to the demand for advanced aseptic fill finish operations.

Companies, including small enterprises and large businesses, outsource their respective fill finish operations to contract service providers. Per the 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, manufacturers of biological have been observed to outsource more than 30% of their fill finish operations. With the rise in the demand for prefilled syringes and the growing complexity of fill finish processes, outsourcing these operations is likely to increase in the future. Over 100 companies across the globe are providing fill finish services for prefilled syringe manufacturers. To cater to the growing demand of pharmaceutical products, service providers are actively investing in expanding their existing infrastructure and capabilities; they have also expanded their clientele through service agreements over the past few years. As injectables account for ~55% of drug candidates in the global R&D pipeline, the businesses of prefilled syringe manufacturers and associated service providers are also growing. Due to the emergence of the COVID-19 crisis, vaccine development initiatives have increased across the globe,

which significantly boosted the demand for prefilled syringes. Thus, the rising adoption of prefilled syringes for parenteral administration drives the fill finish manufacturing market.

North America Fill Finish Manufacturing Market Overview

The fill finish manufacturing market in the US is anticipated to be the largest and fastest-growing market in the world. Several factors such as extensive research and development activities and advanced manufacturing of innovative biopharmaceutical and pharmaceutical products lead to the growth of the market. The other leading factor for market growth is sustained diversity and large-scale supply of biopharmaceutical and pharmaceutical products across the globe.

The biopharmaceutical industry is among the largest revenue-generating sector in the country. In 2023, it generated more than 1.3 million jobs in the US. Thus, the growth in the biopharmaceutical industry has assisted in maintaining the total economic balance in the country substantially. It generates ~US\$ 550 million in revenue annually. Therefore, it is expected that the rise in research and product development will increase the demand for lyophilization services in the US.

North America Fill Finish Manufacturing Market Revenue and Forecast to 2030 (US\$ Million)

North America Fill Finish Manufacturing Market Segmentation

The North America fill finish manufacturing market is segmented based on product, modality, end user, and country. Based on product, the North America fill finish manufacturing market is bifurcated into consumables and instruments. The consumables segment held a larger market share in 2022. Furthermore, the consumables is sub segmented into prefilled syringes, glass vial/plastic vials, cartridges, and others.

In terms of modality, the North America fill finish manufacturing market is segmented into recombinant proteins, monoclonal antibodies, vaccines, cell therapies and biological therapies, gene therapies, and others. The vaccines segment held the largest market share in 2022.

By end user, the North America fill finish manufacturing market is segmented into contract manufacturing organizations, biopharmaceutical companies, and others. The

contract manufacturing organizations segment held the largest market share in 2022.

Based on country, the North America fill finish manufacturing market is segmented into the US, Canada, and Mexico. The US dominated the North America fill finish manufacturing market share in 2022.

Becton Dickinson and Co, Gerresheimer AG, Groninger and Co GmbH, IMA Industria Macchine Automatiche SpA, Maquinaria Industrial Dara SL, Nipro Medical Europe NV, NNE AS, Optima Packaging Group GmbH, Schott AG, SGD SA, Stevanato Group SpA, Syntegon Technology GmbH, and West Pharmaceutical Services Inc are some of the leading players operating in the North America fill finish manufacturing market.

Contents

1. INTRODUCTION

- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights

3. RESEARCH METHODOLOGY

- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research

4. NORTH AMERICA FILL FINISH MANUFACTURING MARKET LANDSCAPE

- 4.1 Overview
- 4.2 PEST Analysis

5. NORTH AMERICA FILL FINISH MANUFACTURING MARKET - KEY INDUSTRY DYNAMICS

- 5.1 Fill Finish Manufacturing Market - Key Industry Dynamics
- 5.2 Key Market Drivers
 - 5.2.1 Growing Adoption of Prefilled Syringes for Parenteral Administration
 - 5.2.2 Elevating Demand for Biologics
- 5.3 Key Market Restraints
 - 5.3.1 Growing Competition in Biopharmaceutical Contract Manufacturing Industry
- 5.4 Key Market Opportunities
 - 5.4.1 Significant Pipeline for Biologics
- 5.5 Key Future Trends
 - 5.5.1 Single-Use Systems for Aseptic Fill Finish
- 5.6 Impact of Drivers and Restraints:

6. FILL FINISH MANUFACTURING MARKET - NORTH AMERICA MARKET ANALYSIS

7. NORTH AMERICA FILL FINISH MANUFACTURING MARKET ANALYSIS - PRODUCT

7.1 Consumables

7.1.1 Overview

7.1.2 Consumables Market, Revenue and Forecast to 2030 (US\$ Million)

7.2 Instruments

7.2.1 Overview

7.2.2 Instruments Market, Revenue and Forecast to 2030 (US\$ Million)

8. NORTH AMERICA FILL FINISH MANUFACTURING MARKET ANALYSIS - MODALITY

8.1 Recombinant Proteins

8.1.1 Overview

8.1.2 Recombinant Proteins Market, Revenue and Forecast to 2030 (US\$ Million)

8.2 Monoclonal Antibodies

8.2.1 Overview

8.2.2 Monoclonal Antibodies Market, Revenue and Forecast to 2030 (US\$ Million)

8.3 Vaccines

8.3.1 Overview

8.3.2 Vaccines Market, Revenue and Forecast to 2030 (US\$ Million)

8.4 Cell Therapies and Biological Therapies

8.4.1 Overview

8.4.2 Cell Therapies and Biological Therapies Market, Revenue and Forecast to 2030 (US\$ Million)

8.5 Gene Therapies

8.5.1 Overview

8.5.2 Gene Therapies Market, Revenue and Forecast to 2030 (US\$ Million)

8.6 Others

8.6.1 Overview

8.6.2 Others Market, Revenue and Forecast to 2030 (US\$ Million)

9. NORTH AMERICA FILL FINISH MANUFACTURING MARKET ANALYSIS - END USER

9.1 Contract Manufacturing Organizations

9.1.1 Overview

9.1.2 Contract Manufacturing Organizations Market, Revenue and Forecast to 2030 (US\$ Million)

9.2 Biopharmaceutical Companies

9.2.1 Overview

9.2.2 Biopharmaceutical Companies Market, Revenue and Forecast to 2030 (US\$ Million)

9.3 Others

9.3.1 Overview

9.3.2 Others Market, Revenue and Forecast to 2030 (US\$ Million)

10. NORTH AMERICA FILL FINISH MANUFACTURING MARKET - COUNTRY ANALYSIS

10.1 North America Fill Finish Manufacturing Market Revenue Forecasts and Analysis - By Country

10.1.1 US

10.1.1.1 US Fill Finish Manufacturing Market Revenue and Forecasts to 2030 (US\$ Mn)

10.1.1.2 United States Fill Finish Manufacturing Market Breakdown by Product

10.1.1.3 United States Fill Finish Manufacturing Market Breakdown by Consumables

10.1.1.4 United States Fill Finish Manufacturing Market Breakdown by Modality

10.1.1.5 United States Fill Finish Manufacturing Market Breakdown by End User

10.1.2 Canada

10.1.2.1 Canada Fill Finish Manufacturing Market Revenue and Forecasts to 2030 (US\$ Mn)

10.1.2.2 Canada Fill Finish Manufacturing Market Breakdown by Product

10.1.2.3 Canada Fill Finish Manufacturing Market Breakdown by Consumables

10.1.2.4 Canada Fill Finish Manufacturing Market Breakdown by Modality

10.1.2.5 Canada Fill Finish Manufacturing Market Breakdown by End User

10.1.3 Mexico

10.1.3.1 Mexico Fill Finish Manufacturing Market Revenue and Forecasts to 2030 (US\$ Mn)

10.1.3.2 Mexico Fill Finish Manufacturing Market Breakdown by Product

10.1.3.3 Mexico Fill Finish Manufacturing Market Breakdown by Consumables

10.1.3.4 Mexico Fill Finish Manufacturing Market Breakdown by Modality

10.1.3.5 Mexico Fill Finish Manufacturing Market Breakdown by End User

11. INDUSTRY LANDSCAPE

- 11.1 Overview
- 11.2 Growth Strategies in the Fill Finish Manufacturing Market, 2020-2023
- 11.3 Inorganic Growth Strategies
 - 11.3.1 Overview
- 11.4 Organic Growth Strategies
 - 11.4.1 Overview

12. COMPANY PROFILES

12.1 IMA Industria Macchine Automatiche SpA

- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments

12.2 Nipro Medical Europe NV

- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments

12.3 Maquinaria Industrial Dara SL

- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments

12.4 Groninger and Co GmbH

- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments

12.5 SGD SA

- 12.5.1 Key Facts

- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 Optima Packaging Group GmbH
 - 12.6.1 Key Facts
 - 12.6.2 Business Description
 - 12.6.3 Products and Services
 - 12.6.4 Financial Overview
 - 12.6.5 SWOT Analysis
 - 12.6.6 Key Developments
- 12.7 NNE AS
 - 12.7.1 Key Facts
 - 12.7.2 Business Description
 - 12.7.3 Product & Services
 - 12.7.4 Financial Overview
 - 12.7.5 SWOT Analysis
 - 12.7.6 Key Developments
- 12.8 Stevanato Group SpA
 - 12.8.1 Key Facts
 - 12.8.2 Business Description
 - 12.8.3 Products and Services
 - 12.8.4 Financial Overview
 - 12.8.5 SWOT Analysis
 - 12.8.6 Key Developments
- 12.9 Syntegon Technology GmbH
 - 12.9.1 Key Facts
 - 12.9.2 Business Description
 - 12.9.3 Products and Services
 - 12.9.4 Financial Overview
 - 12.9.5 SWOT Analysis
 - 12.9.6 Key Developments
- 12.10 West Pharmaceutical Services Inc
 - 12.10.1 Key Facts
 - 12.10.2 Business Description
 - 12.10.3 Products and Services
 - 12.10.4 Financial Overview
 - 12.10.5 SWOT Analysis

- 12.10.6 Key Developments
- 12.11 Gerresheimer AG
 - 12.11.1 Key Facts
 - 12.11.2 Business Description
 - 12.11.3 Products and Services
 - 12.11.4 Financial Overview
 - 12.11.5 SWOT Analysis
 - 12.11.6 Key Developments
- 12.12 Schott AG
 - 12.12.1 Key Facts
 - 12.12.2 Business Description
 - 12.12.3 Products and Services
 - 12.12.4 Financial Overview
 - 12.12.5 SWOT Analysis
 - 12.12.6 Key Developments
- 12.13 Becton Dickinson and Co
 - 12.13.1 Key Facts
 - 12.13.2 Business Description
 - 12.13.3 Products and Services
 - 12.13.4 Financial Overview
 - 12.13.5 SWOT Analysis
 - 12.13.6 Key Developments

13. APPENDIX

- 13.1 About Us
- 13.2 Glossary of Terms

I would like to order

Product name: North America Fill Finish Manufacturing Market Forecast to 2030 - Regional Analysis - by Product (Consumables {Prefilled Syringes, Glass Vial/Plastic Vials, Cartridges, and Others} and Instruments), Modality (Recombinant Proteins, Monoclonal Antibodies, Vaccines, Cell Therapies and Biological Therapies, Gene Therapies, and Others), and End User (Contract Manufacturing Organizations, Biopharmaceutical Companies, and Others)

Product link: <https://marketpublishers.com/r/NAC913650658EN.html>

Price: US\$ 2,485.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NAC913650658EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970